UNC Lineberger’s Channing Der, PhD, Kenan Distinguished Professor in the UNC School of Medicine Department of Pharmacology, was corresponding author of a paper published in Science Signaling.
The study identified a potential therapeutic target for patients with KRAS-mutant pancreatic ductal adenocarcinoma. Der and his colleagues described in the paper the use of a screening strategy that they believe could be used more broadly.
The study, as well as the listing of the co-authors, is available online.